Noveome is advancing its ST266 platform biologic, a first-of-its-kind, multi-targeted secretome containing hundreds of biologically active proteins and other factors crucial to neuroprotection, the modulation of inflammation, cell recovery and healing. We believe this novel platform biologic holds significant clinical potential across a range of important underserved conditions in ophthalmology, neurology, dermatology—and beyond.
